

Medical Drugs Exclude At Launch List

Effective December 22, 2023



This list contains provider-administered drugs that are newly approved by the Food and Drug Administration (FDA). Drugs on this list are being evaluated by PreferredOne for safety, efficacy, and coverage consideration. Completion of review and decision of coverage will be made within 12 months of FDA approval. Prior to review and decision, these medications will not be covered. For more information, see Pharmacy Policy PP/R001 – Review of New FDA-Approved Drugs and Clinical Indications.

DRUG TRADE NAME	TARGET INDICATION	FDA APPROVAL	REMOVAL FROM LIST
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), subcutaneous injection	Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive	6/20/2023	6/20/2024
Elevidys (delandistrogene moxeparvovec-rokl)	Treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.	6/22/2023	6/22/2024
Rystiggo (rozanolixizumab-noli)	Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or antimuscle-specific tyrosine kinase (MuSK) antibody positive	6/27/2023	6/27/2024
Roctavian (valoctocogene roxaparvovec-rvox)	Treatment of adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test	6/29/2023	6/29/2024
Vanflyta (quizartinib)	Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive as detected by an FDA-approved test	7/20/2023	7/20/2024
Izervay (avacincaptad pegol intravitreal solution)	Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)	8/4/2023	8/4/2024
Talvey (talquetamab-tgvs)	Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody	8/9/2023	8/9/2024
Elrexfio (elranatamab-bcmm)	Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody	8/14/2023	8/14/2024
Daxxify (daxibotulinumtoxinA-lanm)	Treatment of cervical dystonia in adult patients	8/14/2023	8/14/2024

DRUG TRADE NAME	TARGET INDICATION	FDA APPROVAL	REMOVAL FROM LIST
Hepzato Kit (melphalan/hepatic delivery system)	A liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation	8/14/2023	8/14/2024
Veopoz (pozelimab-bbfg)	Treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease	8/18/2023	8/18/2024
Eylea HD (afibercept)	Treatment of Neovascular (Wet) age-related macular degeneration; Diabetic macular edema; and Diabetic retinopathy	8/18/2023	8/18/2024
Tyruko (natalizumab-szin)	Indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults	8/25/2023	8/25/2024
Rivfloza (nedosiran)	Treatment to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function	9/29/2023	9/29/2024
Tofidence (tocilizumab-bavi)	Treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs); patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (PJIA); patients 2 years of age and older with active systemic juvenile idiopathic arthritis (SJIA)	9/29/2023	9/29/2024
Cosentyx (secukinumab) IV formulation	Treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)	10/06/2023	10/06/2024
Zilbrysq (zilucoplan)	Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive	10/17/2023	10/17/2024
Zymfentra (infliximab-dyyb)	Maintenance treatment of moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously; moderately to severely active Crohn's disease following treatment with an infliximab product administered IV	10/23/2023	10/23/2024
Loqtorzi (toripalimab-tpzi)	In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC). As a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy	10/27/2023	10/27/2024

DRUG TRADE NAME	TARGET INDICATION	FDA APPROVAL	REMOVAL FROM LIST
Wezlana (ustekinumab-auub)	Patients 6 years and older with moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy. Patients 6 years and older with active psoriatic arthritis (PsA). Adult patients with moderately to severely active Crohn's disease (CD), and adult patients with moderately to severely active ulcerative colitis (UC)	10/31/2023	10/31/2024
Fruzaqla (fruquintinib)	Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) therapy, and, if RAS wild-type and medically appropriate, an anti-epidermal growth factor receptor (EGFR) therapy	11/8/2023	11/8/2024
Adzynma (ADAMTS13, recombinant-krhn)	Prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP)	11/9/2023	11/9/2024
Ryzneuta (efbemalenograstim alfa-vuxw)	To decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.	11/16/2023	11/16/2024
Avzivi (bevacizumab-tjnj)	To decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.	12/06/2023	12/06/2024
Casgevy (exagamglogene autotemcel)	Treatment of SCD in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).	12/08/2023	12/08/2024
Lyfgenia (lovotibeglogene autotemcel)	Treatment of SCD in patients 12 years and older with a history of vaso-occlusive events (VOEs).	12/08/2023	12/08/2024
Alyglo (immune globulin intravenous, human-stwk)	Treatment of primary humoral immunodeficiency in adults.	12/19/2023	12/19/2024